Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Dan Apter, Yvette Zimmerman, Louise Beekman, Marie Mawet, Catherine Maillard, Jean-Michel Foidart & Herjan J. T. Coelingh Bennink. (2017) Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. The European Journal of Contraception & Reproductive Health Care 22:4, pages 260-267.
Read now
Read now
Iñaki Lete & Oihane Lapuente. (2016) Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review. Open Access Journal of Contraception 7, pages 117-125.
Read now
Read now
Lesley L Breech & Paula K Braverman. (2009) Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. International Journal of Women's Health 1, pages 85-95.
Read now
Read now
Filipa M. B. Lã, David M. Howard, William Ledger, Jane W. Davidson & Georgina Jones. (2009) Oral contraceptive pill containing drospirenone and the professional voice: An electrolaryngographic analysis. Logopedics Phoniatrics Vocology 34:1, pages 11-19.
Read now
Read now
Andrea J Rapkin & Sharon A Winer. (2008) The pharmacologic management of premenstrual dysphoric disorder. Expert Opinion on Pharmacotherapy 9:3, pages 429-445.
Read now
Read now
Domenico De Berardis, Nicola Serroni, Rosa Maria Salerno & Filippo Maria Ferro. (2007) Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Therapeutics and Clinical Risk Management 3:4, pages 585-590.
Read now
Read now
Andrea J Rapkin & Sharon A Winer. (2007) Drospirenone: a novel progestin. Expert Opinion on Pharmacotherapy 8:7, pages 989-999.
Read now
Read now
Jan Endrikat, Mirella Sandri, Christoph Gerlinger, Alexander Rübig, Werner Schmidt & Michel Fortier. (2007) A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 μg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. The European Journal of Contraception & Reproductive Health Care 12:3, pages 220-228.
Read now
Read now
Jean-Michel Foidart & Thomas Faustmann. (2007) Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17α-spirolactone-derived progestogen. Gynecological Endocrinology 23:12, pages 692-699.
Read now
Read now
Uriel Halbreich. (2005) Algorithm for treatment of Premenstrual Syndromes (PMS): Experts' recommendations and limitations. Gynecological Endocrinology 20:1, pages 48-56.
Read now
Read now
M. Sillem, R. Schneidereit, R. Heithecker & A. O. Mueck. (2003) Use of an oral contraceptive containing drospirenone in an extended regimen. The European Journal of Contraception & Reproductive Health Care 8:3, pages 162-169.
Read now
Read now
C. Gerlinger, J. Endrikat, E. A. van der Meulen, T. O. M. Dieben & B. Düsterberg. (2003) Recommendation for confidence interval and sample size calculation for the Pearl Index. The European Journal of Contraception & Reproductive Health Care 8:2, pages 87-92.
Read now
Read now
D. Apter, A. Borsos, W. Baumgärtner, G.-B. Melis, D. Vexiau-Robert, A. Colligs-Hakert, M. Palmer & S. Kelly. (2003) Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. The European Journal of Contraception & Reproductive Health Care 8:1, pages 37-51.
Read now
Read now
Anna Glasier. (2002) New developments in contraceptive drugs for use by women. Expert Opinion on Investigational Drugs 11:9, pages 1239-1251.
Read now
Read now
H. Blode, W. Wuttke, W. Loock, G. Röll & R. Heithecker. (2000) A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. The European Journal of Contraception & Reproductive Health Care 5:4, pages 256-264.
Read now
Read now
Articles from other publishers (85)
Jean Michel Foidart, Kristina Gemzell-Danielsson, Ali Kubba, Jonathan Douxfils, Mitchell D. Creinin & Ulysse Gaspard. (2023) The benefits of estetrol addition to drospirenone for contraception. AJOG Global Reports 3:4, pages 100266.
Crossref
Crossref
Jeppe B Schroll, Amanda Y Black, Cindy Farquhar & Innie Chen. (2023) Combined oral contraceptive pill for primary dysmenorrhoea. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Siyan Ma & Sae Jin Song. (2023) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2023:6.
Crossref
Crossref
Larisa I. Maltseva & Julia V. Garifullova. (2022) Predictable benefits of folate-containing combined oral contraceptives after abortion in women: review. Gynecology 24:2, pages 72-79.
Crossref
Crossref
Wan-Lin Zhang, Zhe Dong, Jun-Yan Zhang, Min-Zhi Lyu, Wei Zhang, Jian-Lei Huang & Xin Yang. (2021) Comparison of Risks of Thromboembolism of Drospirenone-Containing and Nondrospirenone -Containing Combined Oral Contraceptive Use: A Meta-Analysis. Reproductive and Developmental Medicine 5:3, pages 154-160.
Crossref
Crossref
Franklin José Espitia De La Hoz. (2021) Indicaciones de la drospirenona más allá de la anticoncepción.. Revista Ciencias Biomédicas 10:2, pages 120-128.
Crossref
Crossref
Dan Martin, Simon B. Cooper, Jonathan C.Y. Tang, William D. Fraser, Craig Sale & Kirsty J. Elliott-Sale. (2021) Bone metabolic marker concentrations across the menstrual cycle and phases of combined oral contraceptive use. Bone 145, pages 115864.
Crossref
Crossref
Xin Sun, Fangbo Qian, Yaojuan He, Xiangying Gu & Wen Di. (2020) Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study. Advances in Therapy 37:2, pages 906-917.
Crossref
Crossref
Mariagrazia StracquadanioMariagrazia Stracquadanio. 2020. Managing Women’s Hyperandrogenism. Managing Women’s Hyperandrogenism
35
83
.
A R Khachaturian, E V Misharina & M I Yarmolinskaya. (2018) Efficacy and safety of drospirenone-containing microdosage combined oral contraceptive use with starting contraception. Gynecology 20:2, pages 9-13.
Crossref
Crossref
Erin E. Tracy. (2017) Contraception. Obstetrics and Gynecology Clinics of North America 44:2, pages 143-158.
Crossref
Crossref
Diana Mansour. (2017) Postponing menstruation: choices and concerns. Journal of Family Planning and Reproductive Health Care 43:2, pages 160-161.
Crossref
Crossref
David R. Kattan & Ronald T. Burkman. 2014. Contraception for the Medically Challenging Patient. Contraception for the Medically Challenging Patient
237
253
.
David R. Kattan & Ronald T. Burkman. 2014. Contraception for the Medically Challenging Patient. Contraception for the Medically Challenging Patient
237
253
.
José A. Guerra, Francisco López-Muñoz & Cecilio Álamo. (2013) Progestins in Combined Contraceptives. Journal of Experimental & Clinical Medicine 5:2, pages 51-55.
Crossref
Crossref
E. Anne MacGregor. (2013) Contraception and Headache. Headache: The Journal of Head and Face Pain 53:2, pages 247-276.
Crossref
Crossref
Ramzi Finan, Abeer Wasfi Annab, Salwa Abdalla, Farid Bedran, Mazen El-Zibdeh, Lina Shahen, Christoph Gerlinger, Erich Solomayer, Kubilay Ertan & Jan Endrikat. (2013) A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria. Health 05:07, pages 39-44.
Crossref
Crossref
Laureen M Lopez, Mario Chen, Deborah Hilgenberg, Julie Denison & Gretchen Stuart. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Anita L Nelson. (2012) Comprehensive Evaluation of Safyral® 2012. Women's Health 8:6, pages 619-633.
Crossref
Crossref
Yuzuru Anzai, Doris Heger-Mahn, Ilka Schellschmidt & Joachim Marr. (2012) Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women. Contraception 86:1, pages 28-34.
Crossref
Crossref
Joachim Marr, Christoph Gerlinger & Michael Kunz. (2012) A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30μg/drospirenone 3mg administered in a 21/7 regimen versus ethinylestradiol 20μg/drospirenone 3mg administered in a 24/4 regimen. European Journal of Obstetrics & Gynecology and Reproductive Biology 162:1, pages 91-95.
Crossref
Crossref
Laureen M Lopez, Adrian A Kaptein & Frans M Helmerhorst. (2012) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Franca Fruzzetti. (2012) Beyaz®: An Oral Contraceptive Fortified with Folate. Women's Health 8:1, pages 13-19.
Crossref
Crossref
Leena Anttila, Walter Neunteufel, Felice Petraglia, Joachim Marr & Michael Kunz. (2011) Cycle Control and Bleeding Pattern of a 24/4 Regimen of Drospirenone 3 mg/Ethinylestradiol 20 μg Compared with a 21/7 Regimen of Desogestrel 150 μg/Ethinylestradiol 20 μg. Clinical Drug Investigation 31:8, pages 519-525.
Crossref
Crossref
Theresa A Lawrie, Frans M Helmerhorst, Nandita K. Maitra, Regina Kulier, Kitty Bloemenkamp & A Metin Gülmezoglu. (2011) Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hakan Coksuer, Mustafa Koplay, Fatih Oghan, Cengiz Coksuer, Nadi Keskin & Olcay Ozveren. (2010) Effects of estradiol?drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. Archives of Gynecology and Obstetrics 283:5, pages 1045-1051.
Crossref
Crossref
Daphnee S. Pushparajah, Petra Röhm, Kornelia Höschen, Dagmar Albers & Christina Nowack. (2011) Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®). Clinical Drug Investigation 31:2, pages 121-134.
Crossref
Crossref
Lisa M Keder. (2011) A New Estradiol-Dienogest Oral Contraceptive Marks “The Pill's” 50th Anniversary. American Journal of Therapeutics 18:1, pages 38-44.
Crossref
Crossref
Sue Kelly, Emyr Davies, Simon Fearns, Carol McKinnon, Rick Carter, Christoph Gerlinger & Andrew Smithers. (2010) Effects of Oral Contraceptives Containing Ethinylestradiol with Either Drospirenone or Levonorgestrel on Various Parameters Associated with Well-Being in Healthy Women. Clinical Drug Investigation 30:5, pages 325-336.
Crossref
Crossref
Rogério Bonassi Machado, Nilson Roberto de Melo & Hugo MaiaJr.Jr.. (2010) Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 81:3, pages 215-222.
Crossref
Crossref
F.M. Helmerhorst. 2010. Anticonceptie. Anticonceptie
42
61
.
Chooi L Wong, Cindy Farquhar, Helen Roberts & Michelle Proctor. (2009) Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Maureen Cronin, Ilka Schellschmidt & Jürgen Dinger. (2009) Rate of Pregnancy After Using Drospirenone and Other Progestin-Containing Oral Contraceptives. Obstetrics & Gynecology 114:3, pages 616-622.
Crossref
Crossref
Nevin Sağsöz, Zerrin Orbak, Volkan Noyan, Aykan Yücel, Banu Uçar & Leyla Yıldız. (2009) The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome. Fertility and Sterility 92:2, pages 660-666.
Crossref
Crossref
László Hernádi, Joachim Marr, Dietmar Trummer, Vincenzo De Leo & Felice Petraglia. (2009) Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 80:1, pages 18-24.
Crossref
Crossref
Jan S. Endrikat, Nikola P. Milchev, Aleksandra Kapamadzija, Jadranka Georgievska, Christoph Gerlinger, Werner Schmidt & Sleem Feroze. (2009) Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 79:6, pages 428-432.
Crossref
Crossref
Chooi L Wong, Cindy Farquhar, Helen Roberts & Michelle Proctor. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
C.C. Zouboulis, T. Rabe & C. Bayerl. (2009) Sinn und Unsinn der ästhetischen EndokrinologieSense and nonsense of aesthetic endocrinology. Gynäkologische Endokrinologie 7:1, pages 25-32.
Crossref
Crossref
Laureen M Lopez, Elizabeth E. Tolley, David A Grimes & Mario Chen-Mok. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Johannes Bitzer & Anna M Paoletti. (2009) Added Benefits and User Satisfaction with a Low-Dose Oral Contraceptive Containing Drospirenone. Clinical Drug Investigation 29:2, pages 73-78.
Crossref
Crossref
J Michael Maloney, Peter Dietze, David Watson, Minoo Niknian, Sooji Lee-Rugh, Carole Sampson-Landers & Paul Korner. (2008) Treatment of Acne Using a 3-Milligram Drospirenone/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24/4 Regimen. Obstetrics & Gynecology 112:4, pages 773-781.
Crossref
Crossref
Regine Sitruk-Ware. (2008) Reprint of Pharmacological profile of progestins. Maturitas 61:1-2, pages 151-157.
Crossref
Crossref
Laureen M Lopez, Elizabeth E. Tolley & David A Grimes. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Christine Klipping, Ingrid Duijkers, Dietmar Trummer & Joachim Marr. (2008) Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78:1, pages 16-25.
Crossref
Crossref
Faustino R. Pérez-López. (2008) Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas 60:2, pages 78-91.
Crossref
Crossref
Hans Peter Zahradnik & Aida Hanjalic-Beck. (2008) Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) — an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 77:5, pages 337-343.
Crossref
Crossref
Filipa M.B. Lã, William L. Ledger, Jane W. Davidson, David M. Howard & Georgina L. Jones. (2007) The Effects of a Third Generation Combined Oral Contraceptive Pill on the Classical Singing Voice. Journal of Voice 21:6, pages 754-761.
Crossref
Crossref
Andrea J RapkinMichelle McDonaldSharon A Winer. (2016) Ethinyl Estradiol/Drospirenone for the Treatment of the Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder. Women's Health 3:4, pages 395-408.
Crossref
Crossref
Vincenzo De Leo, Giuseppe Morgante, Paola Piomboni, Maria Concetta Musacchio, Felice Petraglia & Antonio Cianci. (2007) Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertility and Sterility 88:1, pages 113-117.
Crossref
Crossref
Juhani Knuuti, Riikka Kalliokoski, Tuula Janatuinen, Jarna Hannukainen, Kari K. Kalliokoski, Juha Koskenvuo & Stefan Lundt. (2007) Effect of Estradiol-Drospirenone Hormone Treatment on Myocardial Perfusion Reserve in Postmenopausal Women With Angina Pectoris. The American Journal of Cardiology 99:12, pages 1648-1652.
Crossref
Crossref
Surasak Taneepanichskul, Unnop Jaisamrarn & Vorapong Phupong. (2006) Efficacy of Yasmin in premenstrual symptoms. Archives of Gynecology and Obstetrics 275:6, pages 433-438.
Crossref
Crossref
Luis Bahamondes, Santiago Córdova-Egüez, José Enrique Pons & Lee Shulman. (2007) Perspectives on Premenstrual Syndrome/Premenstrual Dysphoric Disorder. Disease Management & Health Outcomes 15:5, pages 263-277.
Crossref
Crossref
Madhavi Mallareddy, Vladimir Hanes & William B White. (2007) Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension. Drugs & Aging 24:6, pages 453-466.
Crossref
Crossref
Patricia Sulak, Sherilyn Willis, Thomas Kuehl, Andrea Coffee & Jeffrey Clark. (2007) Headaches and Oral Contraceptives: Impact of Eliminating the Standard 7-Day Placebo Interval. Headache: The Journal of Head and Face Pain 47:1.
Crossref
Crossref
GIUSEPPE BENAGIANO, CARLO BASTIANELLI & MANUELA FARRIS. (2007) Contraception Today. Annals of the New York Academy of Sciences 1092:1, pages 1-32.
Crossref
Crossref
Santiago Palacios, Jean-Michel Foidart & Andrea R. Genazzani. (2006) Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 55:4, pages 297-307.
Crossref
Crossref
Andrea L. Coffee, Thomas J. Kuehl, Sherilyn Willis & Patricia J. Sulak. (2006) Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. American Journal of Obstetrics and Gynecology 195:5, pages 1311-1319.
Crossref
Crossref
Martin Sillem. (2016) Yasminelle®: A New Low-Dose Combined Oral Contraceptive Containing Drospirenone. Women's Health 2:4, pages 551-559.
Crossref
Crossref
Bonnie B. DeanJeff E. BorensteinKevin KnightKimberly Yonkers. (2006) Evaluating the Criteria Used for Identification of PMS. Journal of Women's Health 15:5, pages 546-555.
Crossref
Crossref
M. Birkhäuser. (2006) Klinische Bedeutung von gestagenen PartialwirkungenClinical significance of partial gestagen effects. Gynäkologische Endokrinologie 4:1, pages 52-64.
Crossref
Crossref
N. Kurshan & C. Neill Epperson. (2005) Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Archives of Women's Mental Health 9:1, pages 1-14.
Crossref
Crossref
Beate Schultz-Zehden & Ewald Boschitsch. (2006) User Experience with an Oral Contraceptive Containing Ethinylestradiol 30??g and Drospirenone 3mg (Yasmin??) in Clinical Practice. Treatments in Endocrinology 5:4, pages 251-256.
Crossref
Crossref
Jean-Michel Foidart, Patricia J. Sulak, Ilka Schellschmidt & Doris Zimmermann. (2006) The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 73:1, pages 34-40.
Crossref
Crossref
Lisa Kessler Tuchman, Jill S. Huppert, Bin Huang & Gail B. Slap. (2005) Adolescent Use of the Monthly Contraceptive Injection. Journal of Pediatric and Adolescent Gynecology 18:4, pages 255-260.
Crossref
Crossref
Christine Klipping & Joachim Marr. (2005) Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71:6, pages 409-416.
Crossref
Crossref
T. Strowitzki. (2005) Kombinierte Hormonersatztherapie mit 1 mg Östradiol und 2 mg DrospirenonCombined hormone replacement therapy with 1 mg estradiol and 2 mg drospirenone. Gynäkologische Endokrinologie 3:1, pages 55-59.
Crossref
Crossref
Malinee Sangthawan & Surasak Taneepanichskul. (2005) A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms. Contraception 71:1, pages 1-7.
Crossref
Crossref
Regina Kulier, Frans M Helmerhorst, Nandita Maitra & A Metin Gülmezoglu. (2004) Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review. Reproductive Health 1:1.
Crossref
Crossref
Susan R. Johnson. (2004) Premenstrual Syndrome, Premenstrual Dysphoric Disorder, and Beyond: A Clinical Primer for Practitioners. Obstetrics & Gynecology 104:4, pages 845-859.
Crossref
Crossref
Gloria Bachmann, Patricia J. Sulak, Carole Sampson-Landers, Norbert Benda & Joachim Marr. (2004) Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception 70:3, pages 191-198.
Crossref
Crossref
Nandita N Maitra, Regina Kulier, Kitty Bloemenkamp, Frans M Helmerhorst & A Metin Gülmezoglu. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Melissa Calvin. (2004) Navigating the choice of available COC pills. Practice Nursing 15:4, pages 193-197.
Crossref
Crossref
Regine Sitruk-Ware. (2004) Pharmacological profile of progestins. Maturitas 47:4, pages 277-283.
Crossref
Crossref
Andrew M. Kaunitz. (2004) Enhancing oral contraceptive success: the potential of new formulations. American Journal of Obstetrics and Gynecology 190:4, pages S23-S29.
Crossref
Crossref
Wichit Suthipongse & Surasak Taneepanichskul. (2004) An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg levonogestrel/30 μg ethinylestradiol in Thai women. Contraception 69:1, pages 23-26.
Crossref
Crossref
A. Ramírez Hidalgo & A. Avecilla Palau. (2004) Novedades en anticoncepción. FMC - Formación Médica Continuada en Atención Primaria 11:6, pages 314-331.
Crossref
Crossref
Nikki B. Zite & Lee P. Shulman. (2003) New options in contraception for teenagers. Current Opinion in Obstetrics and Gynecology 15:5, pages 385-389.
Crossref
Crossref
Erin C. Raney & Julie Méthot. (2016) Recent Advances in Hormonal and Barrier Contraception. Journal of Pharmacy Practice 16:3, pages 209-217.
Crossref
Crossref
Patricia Aikins Murphy. (2003) New Methods of Hormonal Contraception. The Nurse Practitioner 28:2, pages 11-21.
Crossref
Crossref
Torbj??rn B??ckstr??m, Lotta Andreen, Vita Birzniece, Inger Bj??rn, Inga-Maj Johansson, Maud Nordenstam-Haghjo, Sigrid Nyberg, Inger Sundstr??m-Poromaa, G??ran Wahlstr??m, Mingde Wang & Di Zhu. (2003) The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome. CNS Drugs 17:5, pages 325-342.
Crossref
Crossref
Sam Rowlands. (2003) Newer progestogens. Journal of Family Planning and Reproductive Health Care 29:1, pages 13-16.
Crossref
Crossref
Anna Glasier. (2002) Contraception – past and future. Nature Medicine 8:S10, pages S3-S6.
Crossref
Crossref
H. P. G. Schneider. 2002. Women’s Health and Menopause. Women’s Health and Menopause
91
102
.
Frank Lüdicke, Elisabeth Johannisson, Frans M Helmerhorst, Aldo Campana, Jean-Michel Foidart & Renate Heithecker. (2001) Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium. Fertility and Sterility 76:1, pages 102-107.
Crossref
Crossref
Uwe Fricke & Ulrich Schwabe. 2001. Arzneiverordnungs-Report 2001. Arzneiverordnungs-Report 2001
23
71
.